No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
AKBA Akebia Therapeutics
- 1.0100
- -0.0400-3.81%
Close Jun 18 16:00 ET
- 1.0000
- -0.0100-0.99%
Post 19:55 ET
211.69MMarket Cap-4590P/E (TTM)
1.0500High1.0100Low1.76MVolume1.0400Open1.0500Pre Close1.80MTurnover0.86%Turnover RatioLossP/E (Static)209.60MShares2.480052wk High-7.77P/B205.83MFloat Cap0.780152wk Low--Dividend TTM203.80MShs Float31.0000Historical High--Div YieldTTM3.81%Amplitude0.2410Historical Low1.0240Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 3, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference
Breakeven On The Horizon For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) future prospects. Akebia Therapeutics, Inc., a biopharmaceutic
Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
Comments
$Akebia Therapeutics (AKBA.US)$ any reason why this stock is underperforming?
$Akebia Therapeutics(AKBA.US$ .. what happened?
$Akebia Therapeutics(AKBA.US$ .. ma be drop to below 1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg